Lemont, Illinois Clinical Trials

A listing of Lemont, Illinois clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 72 clinical trials
Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

CREST: Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with Subcutaneous anti-PD-1 Treatment Phase 3 Design with 3 study Arms (A, B and C). Arms A and B consists of two study drugs, PF-06801591 plus BCG. Arm C consists of one study drug, BCG. The study is designed …

PMG Research, Inc. d/b/a PMG Research of DuPage Medical Group
 (7.7 away) Contact site
  • 10 views
  • 01 Aug, 2021
  • +218 other locations
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer Compared to Nab-paclitaxel+Gemcitabine Treatment

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for …

Edward Hospital
 (9.4 away) Contact site
  • 31 views
  • 01 Aug, 2021
  • +273 other locations
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate …

androgen
gonadotropin releasing hormone
prostate adenocarcinoma
ct scan
progressive disease
Research Site
 (7.9 away) Contact site
  • 200 views
  • 23 Jul, 2021
  • +194 other locations
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab Followed by Maintenance Durvalumab Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

Research Site
 (6.8 away) Contact site
  • 84 views
  • 31 Jul, 2021
  • +292 other locations
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and teeth. Drugs used in chemotherapy, …

monoclonal antibodies
neutrophil count
platelet count
folfiri
vitamin d
Loyola Center for Health at Burr Ridge
 (3.4 away) Contact site
  • 65 views
  • 27 Jul, 2021
  • +978 other locations
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with an selective serotonin reuptake …

American Medical Research, Inc.
 (9.2 away) Contact site
  • 0 views
  • 31 Jul, 2021
  • +115 other locations
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart Failure (HF) events, including HF hospitalization and urgent visits …

b-type natriuretic peptide
heart failure
diuretic therapy
stroke
ejection fraction
Advocate Good Samaritan Hospital
 (6.9 away) Contact site
  • 0 views
  • 01 Aug, 2021
  • +778 other locations
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy.

gemcitabine
invasive bladder cancer
gilbert's syndrome
neutrophil count
radical cystectomy
DuPage Medical Group
 (7.9 away) Contact site
  • 0 views
  • 29 Jul, 2021
  • +315 other locations
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

preventive medication
headache
lasmiditan
ly573144
AMITA Health Pediatric Specialty Group
 (6.6 away) Contact site
  • 122 views
  • 26 Jul, 2021
  • +237 other locations
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.

acute treatment
ly573144
lasmiditan
migraine in children
AMITA Health Pediatric Specialty Group
 (6.6 away) Contact site
  • 129 views
  • 24 Jul, 2021
  • +238 other locations